Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04398485 · ClinicalTrials.gov registry record · Phase 1
A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma
A Phase 1 study, sponsored by Ionis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT04398485 is a Phase 1 study that has completed, run by Ionis Pharmaceuticals. The registered enrollment target is 23 participants.
The verdict
NCT04398485, a Phase 1 study, has completed, sponsored by Ionis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the maximum-tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of ION251 in patients with relapsed/refractory multiple myeloma.
Interventions
- DRUG ION251
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2021-01-20 |
| Est. Completion | 2024-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04398485
The ClinicalTrials.gov registry entry for NCT04398485 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ionis Pharmaceuticals, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ION251 is the first listed.
NCT04398485 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04398485 about?
NCT04398485 is a clinical study titled "A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma". The purpose of this study is to determine the maximum-tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of ION251 in patients with relapsed/refractory multiple myeloma.
What is the current status of trial NCT04398485?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2021-01-20. Estimated completion is 2024-09-30.
What interventions are being tested in trial NCT04398485?
The interventions under investigation include: ION251 (DRUG).
Who is sponsoring clinical trial NCT04398485?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.